RACIAL DIFFERENCES IN IFN TRANSCRIPTIONAL RESPONSE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 慢性丙型肝炎病毒是美国最常见的肝病之一。它与进行性肝纤维化、肝硬变和肝细胞癌风险增加有关。大约有240万美国人患有慢性丙型肝炎，非裔美国人的感染率(3.2%)高于高加索人口(1.5%)。丙型肝炎相关性肝硬变的死亡率和由丙型肝炎病毒引起的肝细胞癌的发病率似乎正在增加，预计这些增加将不成比例地影响非裔美国人。与高加索人、墨西哥裔美国人和亚洲人相比，非洲裔美国人患者对基于干扰素(干扰素)的治疗的应答率较低，这一事实放大了这一威胁。非裔美国人对抗病毒治疗相对缺乏反应的原因尚不清楚。这项建议寻求使用复杂的DNA微阵列分析在肝细胞(病毒复制的细胞位置)和外周血淋巴细胞(免疫应答细胞的一个隔室)中诱导的转录变化，以努力更好地了解种族和宿主遗传因素如何影响丙型肝炎病毒感染中的干扰素反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic hepatitis C virus (HCV) is one of the most prevalent diseases of the liver in the United States. It is associated with progressive hepatic fibrosis, cirrhosis and increased risk of hepatocellular carcinoma. Approximately 2.4 million Americans have chronic hepatitis C infection and the rate is higher among the African Americans (3.2%) than among the Caucasian population (1.5%). The mortality rates for hepatitis C-related cirrhosis and the incidence of hepatocellular carcinoma due to HCV appear to be increasing, and these increases are expected to disproportionably affect African Americans. This threat is magnified by the fact that African American patients have a lower rate of response to alpha interferon (IFN gamma) based therapy compared to Caucasian, Mexican American and Asian patients. The reasons for the relative lack of response to antiviral therapy among African Americans are not clear. This proposal seeks to use sophisticated DNA microarray analyses of the transcriptional changes induced in hepatocytes (cellular locus of viral replication) and peripheral blood lymphoctes (one compartment of immune responder cells) in an effort to better understand how racial and host genetic factors influence interferon response in HCV infection.